crf01 ae do we need a customized ccr5 antagonist
play

CRF01_AE: Do we need a customized CCR5 antagonist treatment recommendation? Nico Pfeifer Max Planck Insitute for Informatics HIV coreceptor usage HIV coreceptor usage HIV coreceptor usage HIV coreceptor usage CRF01_AE update Recent

0 downloads 1 Views 601 KB Size Report
  1. CRF01_AE: Do we need a customized CCR5 antagonist treatment recommendation? Nico Pfeifer Max Planck Insitute for Informatics

  2. HIV coreceptor usage

  3. HIV coreceptor usage

  4. HIV coreceptor usage

  5. HIV coreceptor usage

  6. CRF01_AE update • Recent papers report high proportions of X4- capable CRF01_AE infected patients – Mulinge et al. 2013, PLoS ONE – Wai-Chi To et al. 2013, AIDS Res Hum Retroviruses. • Overestimation of X4-capable or other reasons?

  7. Could be confounded http://www.hivviralload.com/blog/2008/11/25/the-hiv-subtype-picture.html

  8. Genetic tropism test Adapted from: T. Lengauer, N. Pfeifer, and R. Kaiser Personalized HIV therapy to control drug resistance Drug Discovery Today: Technologies 2014, 11, pp 57-64

  9. Genetic tropism test Adapted from: T. Lengauer, N. Pfeifer, and R. Kaiser Personalized HIV therapy to control drug resistance Drug Discovery Today: Technologies 2014, 11, pp 57-64

  10. Genetic tropism test Standard geno2pheno[coreceptor] version [1] New geno2pheno-C_NGS-Sanger version [2] 1. Lengauer et al. 2007, Nature Biotechnol. 2. Pfeifer and Lengauer 2012, Bioinformatics

  11. Geno2pheno-C_NGS-Sanger Training Prediction Pfeifer and Lengauer 2012, Bioinformatics

  12. Could be improved? • Collaboration with Nagoya Medical Center (Japan) and Klimkait et al. (InPheno, Uni Basel) – 297 V3 loop sequences of CRF01_AE – Discordance between standard geno2pheno[coreceptor] [1] and new version [2] for certain cases (X4-capable / R5) – Selected 21 samples with largest discordance as well as 5 samples with X4 agreement (control) – PhenXR phenotypes measured in Basel 1. Lengauer et al. 2007, Nature Biotechnol. 2. Pfeifer and Lengauer 2012, Bioinformatics

  13. Current results • 17 samples successfully phenotyped – 14/15 calls with X4-capable / R5 (old / new G2P) were phenotyped as R5 (the other one was mixed-dual according to PhenXR) – Only 2 of the X4/X4 calls could be phenotyped (both R5 according to PhenXR) • Conclusions – It seems as if calling CRF01_AEs R5 when new tool confidently calls it R5 is better than using the old calls – Need more samples for intermediate range

  14. Thanks to … Thomas Lengauer Rolf Kaiser Thomas Klimkait Séverine Louvel Wataru Sugiura Masakazu Matsuda Yoshiyuki Yokomaku

  15. Thanks to … Thomas Lengauer Rolf Kaiser Thomas Klimkait Séverine Louvel Wataru Sugiura Masakazu Matsuda Yoshiyuki Yokomaku

Recommend Documents


ccr5 antagonist ccr5 antagonist drug development issues
CCR5 Antagonist CCR5 Antagonist Drug

CCR5 Antagonist CCR5 Antagonist Drug Development Issues Drug Development

alcohol antagonists
Alcohol Antagonists 1 What is an

Alcohol Antagonists 1 What is an alcohol antagonist? An alcohol antagonist

recommendations for determining hiv 1 coreceptor usage
Recommendations for determining HIV-1

Recommendations for determining HIV-1 coreceptor usage CCR5 antagonists proved

bonn 24 04 2009 bonn 24 04 2009 clinical use of clinical
Bonn, 24.04.2009 Bonn, 24.04.2009

Bonn, 24.04.2009 Bonn, 24.04.2009 Clinical Use of Clinical Use of CCR5

arevir meeting k ln 12 04 2013 ccr5 longitudinal was tun
AREVIR-Meeting, Kln 12.04.2013 CCR5

AREVIR-Meeting, Kln 12.04.2013 CCR5 longitudinal was tun bei

arevir 11 04 2008
AREVIR 11.04.2008 CCR5 Antagonists

AREVIR 11.04.2008 CCR5 Antagonists Antagonists CCR5 In Clinical Clinical

treatment of hiv and ebv associated lymphoma by allogenic
Treatment of HIV and EBV associated

Treatment of HIV and EBV associated lymphoma by allogenic CCR5 32 blood stem

what is customized employment
What is Customized Employment? Laura

What is Customized Employment? Laura Owens, Ph.D., CESP September 12, 2018

clopidogrel
CLOPIDOGREL A second-generation

P he hen G en ene P 2 Y 12 12 T es est 1 CLOPIDOGREL A second-generation

journal
Journal The Disruptive Effects of the

11/13/2012 Journal The Disruptive Effects of the CB 1 Receptor Antagonist

calculation of the minimum anticipated biological effect
Calculation of the Minimum Anticipated

Calculation of the Minimum Anticipated Biological Effect Level (MABEL) and 1

independent novel project google slides document criteria
Independent Novel Project: Google

Independent Novel Project: Google Slides Document Criteria Students will read

apixaban vs vka and aspirin vs placebo in patients with
Apixaban vs VKA and Aspirin vs Placebo

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation

reduces fasting and postprandial glucose in a
Reduces Fasting and Postprandial

The Glucagon Receptor Antagonist LGD-6972 Reduces Fasting and Postprandial

disclosure
DISCLOSURE No disclosures, financial,

DISCLOSURE No disclosures, financial, or otherwise to declare ANATOMY

hif 2 hif 2 knock out inhibits tumor growth 1 2 arnt pvhl
HIF 2 HIF 2 knock out inhibits

5/4/2016 Disclosure Information PT2385: HIF 2 Antagonist for the Treatment

opioid overdose prevention
OPIOID OVERDOSE PREVENTION Guidance

OPIOID OVERDOSE PREVENTION Guidance for Implementing Overdose Prevention in

seelos therapeutics
SEELOS THERAPEUTICS June 2019

We are a responsibly - driven company focused on achieving the most

case presentation case presentation
Case Presentation Case Presentation

Case Presentation Case Presentation 79 year old gentleman underwent CABG 10

intracoronary compared with intravenous bolus abciximab
Intracoronary Compared with Intravenous

Intracoronary Compared with Intravenous Bolus Abciximab Application During

case presentation of st segments elevation in lead avr
CASE PRESENTATION OF ST SEGMENTS

Dr. Sudarshan subedi et al., IJSIT, 2018, 7(2), 205-210 CASE PRESENTATION OF

supraventricular tachycardia from a left bundle branch
Supraventricular tachycardia from a

Supraventricular tachycardia from a left bundle branch block-An unusual